Nasally delivered SARS-CoV-2 vaccines: future promise and challenges.
Journal article
Shaw RH., (2023), Lancet Respir Med, 11, 1038 - 1039
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.
Journal article
Hodgson SH. et al, (2022), Clin Transl Sci, 15, 524 - 534
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
Journal article
Dejnirattisai W. et al, (2021), Lancet
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study.
Journal article
Mo Y. et al, (2021), PLoS Med, 18
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Journal article
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.
Journal article
Lumley SF. et al, (2021), Clin Infect Dis, 73, e699 - e709
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article
Liu X. et al, (2021), SSRN Electronic Journal
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
SARS-CoV-2 within-host diversity and transmission
Journal article
Lythgoe KA. et al, (2021), Science (New York, N.Y.), 372
SARS-CoV-2 within-host diversity and transmission.
Journal article
Lythgoe KA. et al, (2021), Science, 372
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891